Aquablation therapy for symptomatic benign prostatic hyperplasia: single center experience in 47 patients

To report procedure process improvements and confirm preserved safety and short-term effectiveness of a second-generation Aquablation device for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in 47 consecutive patients at a single institution.

Aquablation was performed in 47 patients with symptomatic BPH at a single institution. Baseline, perioperative and 3-month urinary function data were collected.

Mean (range) subject age was 66 (50-79) years, and TRUS sized prostate volume was 48 (20-118) cc. A median lobe was present in 25 (53%) and 8 patients had catheter dependent urinary retention. Mean total procedure time was 35 (13-128) minutes and tissue resection time was 4 (1-10) minutes. There were 5 Clavien-Dindo grade I/II and 5 Clavien-Dindo grade III complications recorded in 8 patients. Average hospital stay was 3.1 (1-8) days and duration of urethral catheterization was 1.9 (1-11) days. Mean IPSS score decreased from 24.4 at baseline to 5 points at month 3; IPSS QOL score decreased from 4.5 to 0.3 points; peak urinary flow rate increased from 7.1 to 16.5 mL/s and post void residue decreased from 119 to 43 mL (all p<.01).

This study confirmed procedure process improvements resulting from system enhancements with preservation of safety and effectiveness during use a second-generation device for the treatment of LUTS due to BPH in the largest single institution study to date. This article is protected by copyright. All rights reserved.

BJU international. 2018 Jan 10 [Epub ahead of print]

Mihir M Desai, Abhishek Singh, Shashank Abhishek, Abhishek Laddha, Harshad Pandya, Akbar N Ashrafi, Arvind P Ganpule, Claus G Roehrborn, Andrew J Thomas, Mahesh Desai, Ravindra B Sabnis

USC Institute of Urology, University of Southern California, Los Angeles, CA., Department of Urology, Muljibhai Patel Urological Hospital, Nadiad, India., UT Southwestern Medical Center, Dallas, TX., Princess of Wales Hospital, Wales, United Kingdom.